Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.
about
Early versus delayed erythropoietin for the anaemia of end-stage kidney diseaseErythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysisFrequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patientsLeft Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.Evidence for the prevention and treatment of stroke in dialysis patientsKlotho and phosphate are modulators of pathologic uremic cardiac remodeling.Alterations in cardiac structure and function in hypertensionBenefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to comIntersection of cardiovascular disease and kidney disease: atrial fibrillation.Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysisCardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management.B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis.High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.Cardiac biomarkers and health-related quality of life in new hemodialysis patients without symptomatic cardiac disease.Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study.The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled TrialGender-specific association of decreased estimated glomerular filtration rate and left vertical geometry in the general population from rural Northeast ChinaA longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC studyAssociation of Dialysis Duration with Outcomes after Transplantation in a Japanese Cohort.Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis StudyPlacental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study.Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.Sudden cardiac death in chronic kidney disease: epidemiology and prevention.Most important chronic complications of arteriovenous fistulas for hemodialysis.Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.How Dangerous Is Hyperkalemia?Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.Cardiovascular complications in chronic dialysis patients.Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study.Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.Diastolic dysfunction and high levels of new cardiac biomarkers as risk factors for cardiovascular events and mortality in hemodialysis patients.Hypertension, fluid overload and micro inflammation are associated with left ventricular hypertrophy in maintenance hemodialysis patients.BMI, spKt/V, and SBP but not DBP are related to LVH in Chinese maintenance hemodialysis patients.Renal denervation decreases susceptibility of the heart to ventricular fibrillation in a canine model of chronic kidney disease.N-Terminal pro-brain natriuretic peptide as a predictor of heart failure with preserved ejection fraction in hemodialysis patients without fluid overload.Why does the treatment of anaemia not improve cardiac outcomes in CKD?Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?The intuitive case for β-blockers in patients with ESRD.Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?
P2860
Q24187089-DAEB4F33-13A9-4EFB-9FF0-4EB9CCB87F96Q24187413-B53308D7-E6BC-4C06-97E8-C2ED52804DB2Q24194545-23D2B0C6-DA8A-45EE-856E-F0FA52FF142AQ26773120-7AE993D3-97CE-4C67-9000-B99E3DBAA3F4Q27023274-5ABBFAE2-C74C-4CC2-80DC-E1F1A63226AFQ27342649-B0BE83B7-8DCD-475A-9474-61740A1FC967Q33732380-D91C3FF7-D83E-4F4F-BDEC-7F875854E904Q33960590-DDCDF1C5-3AD8-49AA-B6FF-A60DA580585DQ34040279-0CAEBC30-8667-4149-B521-5930E8399692Q34133189-B46B5C92-AA99-4979-9A34-F684BE33F5FBQ34572435-6B40EFBA-2AC0-4538-8762-518D6FE2BD35Q35043782-B5076375-54BA-43F8-A51A-C3042E0EAC60Q35228547-4C1149EB-F4A8-4CC9-937C-167FFA8B082EQ35674143-80B89E44-9474-4579-9408-48460FE26CBAQ35739189-337D90F5-CD51-46EB-B1B8-D3B95EB92CB1Q36025666-ABBE2624-64CB-4E8E-BA6A-A3BFAB05F1AEQ36249262-43A9EFEA-9787-423C-BAF6-6CD62E7AEDF2Q36652810-6C618C26-9672-4E9A-AF93-658E9FC5B1DAQ36687035-ED289972-7E1B-4D33-9490-30B7A79B2833Q36770929-8E6D2A5D-042D-4F2B-AF75-BF245D29ED6BQ37113344-BFB4C50F-D177-41FB-87CA-056F54AC032DQ37574305-47B7BEDB-FFD0-4A33-9885-C786358ED59AQ37833896-F2FD4620-7E7F-4105-991E-EFB376484B0EQ38057947-FFD64ADC-49A3-4C6D-A46A-95A288C87856Q38258133-7FFD5FA9-9CA5-43C9-B5E4-913451CFE420Q38639874-3A01B00F-31C7-4A3E-862B-07EC07F4D27EQ38727741-E831782B-3AC1-4AAD-AE8A-8A59DFEB1998Q38837657-24857C6D-5642-448F-B23C-E0ACAEB375D0Q38956399-7A755EC6-47EC-4324-9E1F-B6F0D15F4333Q40721152-A79A9A7D-8B38-4DC6-9260-A9490448809DQ40882922-AEBA811D-3D0F-43CC-B2BE-04C03B2F9A62Q43956069-2384797F-3ECA-4C40-8E72-8033F1A1C8ADQ44459137-706F2F3B-5FFB-4075-BCA7-BFB41E1EB95FQ45915059-63287D6B-7531-4D3B-B6D2-38B635243EC4Q47915999-BE44BC0F-F118-4A34-96AD-165CB8D32B9CQ48798746-C5D1F9DE-65B2-437F-A898-33749AE07152Q49064969-1574DA56-E2FD-4F02-AC1A-3726AE94475EQ51139092-DA6D2B33-270C-4571-B006-B939A2133B95Q51636115-7CEADC46-4CDE-49BC-8594-2238E27C41B6Q54320351-01337E62-8EB6-4357-87ED-5221963A9AC1
P2860
Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@ast
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@en
type
label
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@ast
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@en
prefLabel
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@ast
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@en
P2093
P2860
P356
P1476
Left ventricular hypertrophy i ...... t symptomatic cardiac disease.
@en
P2093
Bryan M Curtis
Edward W Randell
Patrick S Parfrey
Robert N Foley
P2860
P304
P356
10.2215/CJN.07761109
P577
2010-04-08T00:00:00Z